CC
NBIX icon

Centiva Capital’s Neurocrine Biosciences NBIX Stock Holding History

Centiva Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,500
Closed -$1.05M – 1894
2025
Q1 		$1.05M Buy
+9,500
New +$1.2M 0.03% 473
2024
Q4 		– Sell
-2,079
Closed -$240K – 2154
2024
Q3 		$240K Sell
2,079
-742
-26% -$102K ﹤0.01% 1716
2024
Q2 		$388K Buy
+2,821
New +$387K 0.01% 1318

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's NBIX Position: Q2 2025 in Review

Centiva Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 9,500 shares — an estimated $1.05M sold.

Centiva Capital first reported a position in NBIX in Q2 2024 and held it in 3 quarters. The position peaked at $1.05M in Q1 2025. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Centiva Capital reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Centiva Capital sold 9,500 Neurocrine Biosciences shares in Q2 2025, an estimated $1.05M.
  • Centiva Capital first reported a position in Neurocrine Biosciences in Q2 2024 and held it in 3 quarters.
  • Centiva Capital's Neurocrine Biosciences position peaked at $1.05M in Q1 2025.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.